Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler

Kralikova, Eva; Kozak, Jiri T.; Rasmussen, Thomas; Gustavsson, Gunnar; Le Houezec, Jacques
January 2009
BMC Public Health;2009, Vol. 9 Issue 1, p433
Academic Journal
Background: Even with effective smoking cessation medications, many smokers are unable to abruptly stop using tobacco. This finding has increased interest in smoking reduction as an interim step towards complete cessation. Methods: This multi-center, double-blind placebo-controlled study evaluated the efficacy and safety of nicotine 4 mg gum or nicotine 10 mg inhaler in helping smokers (N = 314) to reduce or quit smoking. It included smokers willing to control their smoking, and participants could set individual goals, to reduce or quit. The study was placebo-controlled, randomized in a ratio of 2:1 (Active:Placebo), and subjects could choose inhaler or gum after randomization. Outcome was short-term (from Week 6 to Month 4) and long-term (from Month 6 to Month 12) abstinence or reduction. Abstinence was defined as not a single cigarette smoked and expired CO readings of <10 ppm. Smoking reduction was defined as a reduction in number of cigarettes per day by 50% or more versus baseline, verified by a lower-than-baseline CO reading at each visit during the same periods. Results: Significantly more smokers managed to quit in the Active group than in the Placebo group. Sustained abstinence rates at 4 months were 42/209 (20.1%) subjects in the Active group and 9/ 105 (8.6%) subjects in the Placebo group (p = 0.009). Sustained abstinence rates at 12 months were 39/209 (18.7%) and 9/105 (8.6%), respectively (p = 0.019). Smoking reduction did not differ between the groups, either at short-term or long-term. Twelve-month reduction results were 17.2% vs. 18.1%, respectively. No serious adverse events were reported. Conclusion: In conclusion, treatment with 10 mg nicotine inhaler or 4 mg nicotine chewing gum resulted in a significantly higher abstinence rate than placebo. In addition a large number of smokers managed to reduce their cigarette consumption by more than 50% compared to baseline.


Related Articles

  • Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. Yudkin, Patricia; Hey, Kate; Murphy, Michael; Roberts, Sarah; Welch, Sarah; Walton, Robert // BMJ: British Medical Journal (International Edition);7/5/2003, Vol. 327 Issue 7405, p28 

    Discusses abstinence from smoking eight years after participation in randomised controlled trial of the nicotine patch. Lack of studies that investigate abstinence beyond three years; Participants, methods, results; Lack of effectiveness of the patch; Need for more effective ways to help people...

  • Recent Developments in Cigarette Smoking Cessation. Herzog, Thaddeus // Hawaii Medical Journal;Jul2010, Vol. 69 Issue 7, p174 

    The article presents an update and summary of existing evidence-based smoking cessation techniques and medications, based upon the Clinical Practice Guideline "Treating Tobacco Use and Dependence: 2008 Update." The unplanned cold turkey smoking cessation is discussed. It notes that the five most...

  • Characteristics of low‐level smokers. Hyland, Andrew; Rezaishiraz, Hamed; Bauer, Joseph; Giovino, Gary A.; Cummings, K. Michael // Nicotine & Tobacco Research;Jun2005, Vol. 7 Issue 3, p461 

    Average daily cigarette consumption has decreased, and some evidence suggests that the rate of “some day” smoking has increased; however, relatively little is known about low‐level smokers. The present analysis describes and compares low‐level versus heavier smokers,...

  • Massachusetts sets standard.  // Journal of Epidemiology & Community Health;Nov2003, Vol. 57 Issue 11, p915 

    Increasing rates of youth tobacco use in Massachusetts were dramatically reversed after the introduction of a comprehensive tobacco control programme aimed specifically at youth smoking prevention. Researchers used data from the triennial Massachusetts prevalence study, which collects data on...

  • Interventions for treatment-resistant smokers. Fagerström, Karl Olov // Nicotine & Tobacco Research;Sep1999 Supplement 2, Vol. 1, pS201 

    We can understand resistance to treatment in smokers in two ways. First, when there is no awareness that smoking can be responsible for a physical disease, e.g., chronic obstructive lung disease or a dependence disorder. Second, when smokers actually seek treatment but fail to respond...

  • Update on smoking cessation. Fiore, Michael C.; Westman, Eric C.; Theobald, Wendy // Patient Care;Oct2004, Vol. 38 Issue 10, p34 

    Discusses the significance of the tobacco cessation guideline from the U.S. Public Health Service. Recommendations for screening for tobacco use; Pharmacotherapy for smoking cessation; Ways to motivate reluctant smokers to quit. INSETS: Women and smoking;Quit smoking and lose weight with one...

  • Engaging Patients In Tobacco Dependence Treatment: Assessment and Motivational Techniques. Krejci, Jonathan; Foulds, Jonathan // Psychiatric Annals;Jul2003, Vol. 33 Issue 7, p436 

    The article provides clinicians with guidance on the assessment of tobacco use and how to help move patients from assessment toward quitting. The severity of tobacco dependence is assessed. The biochemical measures of nicotine dependence are discussed in detail. The questions used to assess...

  • Assessing dimensions of nicotine dependence: An evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Piper, Megan E.; McCarthy, Danielle E.; Bolt, Daniel M.; Smith, Stevens S.; Lerman, Caryn; Benowitz, Neal; Fiore, Michael C.; Baker, Timothy B. // Nicotine & Tobacco Research;Jun2008, Vol. 10 Issue 6, p1009 

    Considerable research, ranging from survey to clinical to genetic, has utilized traditional measures of tobacco dependence, such as the Fagerstrom Test of Nicotine Dependence (FTND) and the Diagnostic and Statistical Manual (4th ed.) (DSM-IV) criteria, that focus on endpoint definitions of...

  • Best Practice in Group-based Smoking Cessation: Results of a Literature Review Applying Effectiveness, Plausibility, and Practicality Criteria. Manske, Steve; Miller, Susan; Moyer, Cheryl; Phaneuf, Marie Rose; Cameron, Roy // American Journal of Health Promotion;Jul/Aug2004, Vol. 18 Issue 6, p409 

    Objective. Apply a “best practices” model to evidence regarding group smoking cessation to inform organizational decisions about adopting such programs. The best-practices model attempts to integrate rigorous review of evidence with context and practical considerations important to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics